CN106536509B - 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物 - Google Patents
作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物 Download PDFInfo
- Publication number
- CN106536509B CN106536509B CN201580034131.4A CN201580034131A CN106536509B CN 106536509 B CN106536509 B CN 106536509B CN 201580034131 A CN201580034131 A CN 201580034131A CN 106536509 B CN106536509 B CN 106536509B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- cancer
- pharmaceutically
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14382230 | 2014-06-16 | ||
EP14382230.2 | 2014-06-16 | ||
PCT/EP2015/056860 WO2015192981A1 (en) | 2014-06-16 | 2015-03-30 | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106536509A CN106536509A (zh) | 2017-03-22 |
CN106536509B true CN106536509B (zh) | 2020-06-09 |
Family
ID=51136403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580034131.4A Active CN106536509B (zh) | 2014-06-16 | 2015-03-30 | 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9840500B2 (es) |
EP (1) | EP3154957B1 (es) |
JP (1) | JP6527534B2 (es) |
CN (1) | CN106536509B (es) |
AU (1) | AU2015276537B2 (es) |
CA (1) | CA2987978C (es) |
DK (1) | DK3154957T3 (es) |
ES (1) | ES2769648T3 (es) |
WO (1) | WO2015192981A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017102677A1 (en) * | 2015-12-14 | 2017-06-22 | Fundación Para La Investigación Médica Aplicada | 2,4,6,7-tetrasubstituted quinoline compounds as inhibitors of dna methyltransferases |
PL3442947T3 (pl) * | 2016-04-15 | 2023-10-02 | Epizyme, Inc. | Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
WO2017201199A1 (en) * | 2016-05-17 | 2017-11-23 | Duke University | Compositions and methods for the treatment of prader-willi syndrome |
US11433068B2 (en) * | 2016-09-08 | 2022-09-06 | The General Hospital Corporation | Treatment of cancers having alterations within the SWI/SNF chromatin remodeling complex |
ES2910108T3 (es) * | 2016-12-22 | 2022-05-11 | Global Blood Therapeutics Inc | Inhibidores de la histona metiltransferasa |
WO2018119065A1 (en) | 2016-12-22 | 2018-06-28 | Asddr, Llc | Use of histone methyltransferase inhibitors and histone deacetylase inhibitors for therapy of phelan-mcdermid syndrome |
US20200113901A1 (en) * | 2017-03-31 | 2020-04-16 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
EP3612181A4 (en) | 2017-04-21 | 2021-01-06 | Epizyme, Inc. | COMBINATION THERAPIES WITH EHMT2 INHIBITORS |
EP3634962B1 (en) | 2017-06-09 | 2023-05-24 | Global Blood Therapeutics, Inc. | Azaindole compounds as histone methyltransferase inhibitors |
WO2018229139A1 (en) | 2017-06-14 | 2018-12-20 | Fundación Para La Investigación Médica Aplicada | Novel compounds for use in cancer |
US11661410B2 (en) | 2017-08-15 | 2023-05-30 | Global Blood Therapeutics, Inc. | Tricyclic compounds as histone methyltransferase inhibitors |
WO2019036384A1 (en) | 2017-08-15 | 2019-02-21 | Global Blood Therapeutics, Inc. | TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES |
EP3697762A4 (en) * | 2017-10-18 | 2021-04-07 | Epizyme, Inc. | AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS, USED AS EHMT2 INHIBITORS, SALTS THEREOF, AND THEIR METHODS OF SYNTHESIS |
SG11202003162RA (en) * | 2017-10-18 | 2020-05-28 | Epizyme Inc | Methods of using ehmt2 inhibitors in treating or preventing blood disorders |
EP3807248A4 (en) * | 2018-05-29 | 2021-10-27 | Council of Scientific and Industrial Research | BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE |
WO2019243236A1 (en) | 2018-06-18 | 2019-12-26 | Fundación Para La Investigación Médica Aplicada | New anticancer drug combinations |
CN112390791B (zh) * | 2019-08-14 | 2023-08-01 | 复旦大学 | 一类dna甲基转移酶1荧光探针及其用途 |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
CN115160294B (zh) * | 2022-06-27 | 2023-09-29 | 中山大学 | 一种G9a/GLP共价抑制剂及其制备方法及应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001154A1 (en) * | 1997-07-03 | 1999-01-14 | University Of Iowa Research Foundation | Method for inhibiting immunostimulatory dna associated responses |
WO2000076982A1 (en) * | 1999-06-16 | 2000-12-21 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
CN1290698A (zh) * | 1999-10-01 | 2001-04-11 | 弗·哈夫曼-拉罗切有限公司 | 喹啉-4-基衍生物i |
WO2003055866A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
WO2004056352A1 (en) * | 2002-12-19 | 2004-07-08 | Scios, Inc. | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS |
CN101535295A (zh) * | 2006-10-12 | 2009-09-16 | 休普基因公司 | 用于调节dna甲基化的喹啉衍生物 |
CN101889008A (zh) * | 2007-10-12 | 2010-11-17 | 休普基因公司 | 用于调节dna甲基化的喹啉衍生物 |
CN102596200A (zh) * | 2009-11-07 | 2012-07-18 | 默克专利有限公司 | 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类 |
CN102597218A (zh) * | 2009-08-12 | 2012-07-18 | 国立大学法人京都大学 | 用于诱导多能干细胞分化成神经前体细胞的方法 |
WO2013062943A1 (en) * | 2011-10-24 | 2013-05-02 | Glaxosmithkline Intellectual Property Development Limited | New compounds |
WO2013140148A1 (en) * | 2012-03-19 | 2013-09-26 | Imperial Innovations Limited | Quinazoline compounds and their use in therapy |
WO2014072391A1 (en) * | 2012-11-09 | 2014-05-15 | St-Ericsson Sa | Analog to digital conversion method with offset tracking and correction and analog to digital converter implementing the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1088818T3 (da) * | 1999-10-01 | 2005-03-14 | Hoffmann La Roche | Quinolin-4-yl-derivater |
EP1633718B1 (en) * | 2003-06-17 | 2012-06-06 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
US20080175814A1 (en) | 2006-10-12 | 2008-07-24 | Supergen, Inc. | Quinoline derivatives for modulating dna methylation |
TW201111376A (en) * | 2009-06-25 | 2011-04-01 | Amgen Inc | Heterocyclic compounds and their uses |
EP2730558A1 (en) * | 2012-11-08 | 2014-05-14 | Ikerchem, S.L. | Indole derivatives, pharmaceutical compositions containing such indoles and their use as DNA methylation modulators |
JP6338601B2 (ja) * | 2013-03-01 | 2018-06-06 | フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ | ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物 |
-
2015
- 2015-03-30 US US15/315,326 patent/US9840500B2/en active Active
- 2015-03-30 CN CN201580034131.4A patent/CN106536509B/zh active Active
- 2015-03-30 JP JP2016573017A patent/JP6527534B2/ja active Active
- 2015-03-30 WO PCT/EP2015/056860 patent/WO2015192981A1/en active Application Filing
- 2015-03-30 CA CA2987978A patent/CA2987978C/en active Active
- 2015-03-30 EP EP15714185.4A patent/EP3154957B1/en active Active
- 2015-03-30 ES ES15714185T patent/ES2769648T3/es active Active
- 2015-03-30 AU AU2015276537A patent/AU2015276537B2/en active Active
- 2015-03-30 DK DK15714185.4T patent/DK3154957T3/da active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001154A1 (en) * | 1997-07-03 | 1999-01-14 | University Of Iowa Research Foundation | Method for inhibiting immunostimulatory dna associated responses |
WO2000076982A1 (en) * | 1999-06-16 | 2000-12-21 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
CN1290698A (zh) * | 1999-10-01 | 2001-04-11 | 弗·哈夫曼-拉罗切有限公司 | 喹啉-4-基衍生物i |
WO2003055866A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
WO2004056352A1 (en) * | 2002-12-19 | 2004-07-08 | Scios, Inc. | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS |
CN101535295A (zh) * | 2006-10-12 | 2009-09-16 | 休普基因公司 | 用于调节dna甲基化的喹啉衍生物 |
CN101889008A (zh) * | 2007-10-12 | 2010-11-17 | 休普基因公司 | 用于调节dna甲基化的喹啉衍生物 |
CN102597218A (zh) * | 2009-08-12 | 2012-07-18 | 国立大学法人京都大学 | 用于诱导多能干细胞分化成神经前体细胞的方法 |
CN102596200A (zh) * | 2009-11-07 | 2012-07-18 | 默克专利有限公司 | 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类 |
WO2013062943A1 (en) * | 2011-10-24 | 2013-05-02 | Glaxosmithkline Intellectual Property Development Limited | New compounds |
WO2013140148A1 (en) * | 2012-03-19 | 2013-09-26 | Imperial Innovations Limited | Quinazoline compounds and their use in therapy |
WO2014072391A1 (en) * | 2012-11-09 | 2014-05-15 | St-Ericsson Sa | Analog to digital conversion method with offset tracking and correction and analog to digital converter implementing the same |
Non-Patent Citations (3)
Title |
---|
Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by Quinacrine, Chloroquine, and Structurally Related Compounds;Donald E. Macfarlane;《The Journal of Immunology》;19981231;第160卷;全文 * |
Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human;Giuseppe A. M. Giardina;《J. Med. Chem.》;19971231;第40卷(第12期);全文 * |
Synthetic Antimalarials. The Preparation of Certain 4-Amino quinolines1;By Nathan L. Drake;《J. Am. Chem. Soc.》;19460630;第68卷;全文 * |
Also Published As
Publication number | Publication date |
---|---|
US9840500B2 (en) | 2017-12-12 |
EP3154957A1 (en) | 2017-04-19 |
CA2987978C (en) | 2022-08-16 |
AU2015276537B2 (en) | 2019-03-14 |
JP2017524668A (ja) | 2017-08-31 |
AU2015276537A1 (en) | 2017-01-05 |
DK3154957T3 (da) | 2020-02-17 |
CN106536509A (zh) | 2017-03-22 |
ES2769648T3 (es) | 2020-06-26 |
CA2987978A1 (en) | 2015-12-23 |
US20170121316A1 (en) | 2017-05-04 |
JP6527534B2 (ja) | 2019-06-05 |
EP3154957B1 (en) | 2019-11-20 |
WO2015192981A1 (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106536509B (zh) | 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物 | |
JP6754864B2 (ja) | Egfr変異型キナーゼ活性をモジュレートするための化合物および組成物 | |
CN106488910B (zh) | Kras g12c的抑制剂 | |
JP6401773B2 (ja) | Betブロモドメイン阻害剤およびこれを用いる治療方法 | |
TWI551595B (zh) | 2,4-disubstituted benzene-1,5-diamine derivatives and their use, Its preparation of pharmaceutical compositions and pharmaceutical compositions | |
KR101828187B1 (ko) | 신규 축합 피리미딘 화합물 또는 그 염 | |
CN108884097B (zh) | 嘧啶类衍生物、其制备方法和其在医药上的用途 | |
CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
CN112585119A (zh) | 经取代的吲哚及其使用方法 | |
CN107531683B (zh) | Usp7抑制剂化合物及使用方法 | |
JP2016501251A (ja) | がんの治療のための新規二環フェニル−ピリジン/ピラジン | |
US11510915B2 (en) | Anti-tumor effect potentiator using novel biphenyl compound | |
EP3377490A1 (en) | Novel compounds as inhibitors of dna methyltransferases | |
JP2022547294A (ja) | キナーゼ阻害剤としての3,5-ジ置換ピラゾール化合物およびその応用 | |
CN110650961B (zh) | Parp抑制剂、其药物组合物、制备方法和应用 | |
JPWO2018159613A1 (ja) | ピラゾロ[3,4−d]ピリミジン化合物を用いた抗腫瘍効果増強剤 | |
CN115803325B (zh) | 一种egfr抑制剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |